T here has been a substantial amount of evidence accumulated in support of the presence of T lymphocytes in atherosclerotic lesions. 1 -4 T lymphocytes are found not only in advanced lesions but also in early lesions to various extents.
-
4 Some T lymphocytes express class II major histocompatibility complex (MHC II), very late activation antigen (VLA-1), or interleukin-2 (IL-2) receptors, suggesting that these cells are activated. 3 Activated lymphocytes secrete various lymphokines that have been shown to affect the function of vascular cells in vitro and in vivo. 5 Although the exact pathological roles of T lymphocytes in the development of atherosclerosis are not yet clear, it is likely that they modulate functions of endothelial cells (ECs), smooth muscle cells (SMCs), and macrophages (M0s) by producing those lymphokines or via other immunological mechanisms that affect the course of atherogenesis. 6 Interferon gamma (IFN-y) is one of the lymphokines secreted by activated T lymphocytes. It has a wide range of effects on vascular cells in culture. IFN-y induces expression of HLA-DR and other surface antigens on ECs, SMCs, and M0s 7 -10 ; suppresses production of platelet-derived growth factor (PDGF) by ECs 11 ; and decreases production of lipoprotein lipase by M0s.
muscle-specific a-actin. 16 Pretreatment with IFN-y also eliminates the chemotactic response of human SMCs to PDGF. 17 However, the exact effects of IFN-y on SMC proliferation in atherogenesis and its mechanisms of action are not yet clear.
This study was originally designed to confirm the suppressive effects of IFN-y on SMC proliferation and elucidate its mechanisms of action. We found, however, to our surprise that IFN--y stimulated proliferation of SMCs under certain circumstances. In this paper we report that IFN--y stimulates the proliferation of human vascular SMCs by inducing autocrine growth factor(s) and by upregulating the PDGF receptor.
Methods

Cytokines and Antibodies
Recombinant human IFN-y (TRP-2) was supplied by Takeda Pharmaceutical Co., Osaka, Japan. Recombinant human PDGF-AA and -BB were purchased from Pepro Tech Inc., Rocky Hill, N.J. Monoclonal antibodies to human IFN--y and anti-PDGF goat immunoglobulin G were purchased from Interferon Sciences, New Brunswick, N.J., and Collaborative Research, Bedford, Mass., respectively.
Cell Culture
Human vascular SMCs were prepared from the umbilical artery by the method previously described. 15 Cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 20% fetal calf serum, 10 ng/ml basic fibroblast growth factor (bFGF) (Pepro Tech), 100 units/ml streptomycin, and 100 units/ml penicillin. Cultured cells were identified as SMCs by the typical hill-and-valley growth pattern 18 and by immunostaining with monoclonal antibody HHF-35, 19 which stains SMCs but not ECs, M0s, or fibroblasts. SMCs were used for experiments in the third through seventh passages. Swiss 3T3 mouse fibroblasts were obtained from the Japan Cancer Research Resources Bank and maintained in DMEM supplemented with 10% calf serum.
Mitogenesis Assay
SMCs were trypsinized, resuspended in DMEM supplemented with 1% plasma-derived serum (PDS), 18 and seeded at 1.5xl0Vcm 2 in 24-well dishes. The cells were cultured for 5 days without changing the medium, and then IFN-y, other mitogens, or vehicle was added directly to each well. At the times indicated, 37 kBq of [ 3 H]thymidine ([ 3 H]TdR) in a 10-/il volume was added. After 2 or 24 hours the medium was removed, and the cells were then washed once with cold phosphatebuffered saline (PBS) and twice with cold 5% trichloroacetic acid (TCA). TCA-precipitable material was dissolved with 0.2 M NaOH and counted with a Beckman scintillation counter. The mitogenesis assay using Swiss 3T3 cells was performed as described previously. 20 The labeling of nuclei in the S phase with 5-bromo-2'-deoxyuridine (BrdU) was performed by using the cell proliferation kit from Amersham Japan, Tokyo. 21 
Iodination of m I-PDGF-AA
Recombinant human PDGF-AA was iodinated by using Iodo-beads (Pierce Chemical Co.) according to the manufacturer's instructions. Specific activity was 10,000 cpm/ng, and 97% was precipitable in the presence of 10% TCA and 0.25% gelatin.
I25 I-PDGF-BB was purchased from Amersham Japan.
I25 I-PDGF-BB Binding
Detection of PDGF receptors was carried out by a previously reported method. 22 Briefly, SMCs were seeded at 3x10*/well in 24-well dishes and cultured for 5 days as mentioned above. IFN--y or other reagents were added directly to the culture. After a period as mentioned in the figure legends, the medium was removed and cells were washed twice with cold binding rinse (PBS/0.25% bovine serum albumin [BSA]). One milliliter of binding medium (DMEM/25 mM N-hydroxyethylpiperazine-W-2-ethane sulfonic acid, pH 7.4/ 0.25% BSA) containing various concentrations of 125 I-PDGF was added, and the cells were incubated on an oscillating platform at 4°C for 4 hours. After being washed with cold binding rinse four times, the cells were dissolved with solubilizing buffer (1% Triton X-100/ 0.1% BSA/water). Aliquots of the sample were counted with a gamma counter. With the assumption that nonspecific binding is linear with 125 I-PDGF concentrations, it was calculated, based on counts obtained in the presence of 6 pM I25 I-PDGF and 20 ng/ml noniodinated PDGF of the same isoform as the iodinated material. Paired dishes without 125 I-PDGF were processed in the same way and trypsinized for determination of cell numbers.
Northern Blot Analysis
Total cellular RNA was prepared by a method reported by Chomczynski and Sacchi 23 from SMCs. Northern blot analysis was performed as previously described. 24 Total cellular RNA (10 /u.g) was electrophoresed on a 1% agarose gel containing 20 mM 3-(Nmorpholino)propanesulfonic acid, pH 7.0, 50 mM sodium acetate, 5 mM EDTA, and 6% formaldehyde. After staining with ethidium bromide, RNA was transferred to nylon membranes and was fixed by UV irradiation. The cDNA probe for the PDGF-/3 receptor was a gift from Zymogenetics, Seattle, Wash. 25 The filter was hybridized with "P-labeled cDNA probes created by a random-priming DNA labeling method at 50°C in 50% formamide, 50% polyethylene glycol, 7% sodium dodecyl sulfate (SDS), 1 mM EDTA, 0.25 M NaCl, 1.25 M Na 2 HPO 4 , pH 7.2, and 100 jig/ml denatured salmon sperm DNA. The filter was washed twice with 2x saline-sodium citrate 24 and 0.1% SDS for 15 minutes, twice with O.lx saline-sodium citrate and 0.1% SDS for 15 minutes at 65°C, and then autoradiographed by using an intensifying screen for 24-72 hours at -70°C.
Statistical Analysis
The significance of any differences was determined by using a nonpaired Student's t test.
Results
IFN-y Is Indirectly Mitogenic for Vascular SMCs
Human arterial SMCs were growth arrested by maintenance in medium containing 1% PDS for 5 days without changing the medium. Under these conditions, [ did not change for 72 hours (data not shown). The BrdU labeling assay also indicated that SMCs were growth arrested under these conditions ( Figure 1 and Table 1) . When 0-100 units/ml of recombinant human IFN-y was added to those SMCs, pH]TdR incorporation was stimulated in a dose-dependent fashion ( Figure 2 ). IFN--yof 0.1 unit/ml caused a significant increase in fHJTdR incorporation. Maximum stimulation was obtained with 1 unit/ml IFN-y, and this was comparable with the stimulation levels obtained with 5 ng/ml PDGF-BB. IFN-y also accentuated the mitogenic effect of PDGF-BB for these SMCs in a synergistic fashion. However, in contrast to the maximum mitogenic effect of IFN-y alone as observed at 1 unit/ml, the synergistic effect on PDGF-induced mitogenicity continued to increase at 0-100 units/ml IFN-y ( Figure 2 ). The mitogenic activity of IFN-y under these conditions was verified by a BrdU labeling assay and a cell count assay. The results of the BrdU labeling assay showed a good agreement with the results of the [ 3 H]TdR incorporation assay ( Figure 1 and Table 1 ). Although cell multiplication was not remarkable after the cells were starved of medium for 5 days, IFN-y increased the number of SMCs in a dose-dependent fashion to an extent comparable with that achieved with 5 ng/ml PDGF-BB (Table 2) .
Since cytokines sometimes induce the production of other cytokines or growth factors and elicit various effects indirectly through those substances," 26 -27 we studied the time course of mitogenic stimulation by IFN-y. PDGF-BB, a potent mitogen for SMCs, induced the Gi-»S transition 12 hours after addition. In comparison, SMCs stimulated by IFN-y entered the S phase 4-6 hours later than did SMCs stimulated by PDGF (Figure 3 
hours. [
3 H]TdR incorporation stimulated by IFN-y tended to be protracted. The synergistic effect with PDGF-BB became apparent after 16 hours, in accordance with the appearance of mitogenic effects with IFN-y alone, and decreased after the peak was reached at 20 hours after addition.
Time-course experiments suggested that the mitogenic activity of IFN-y was mediated by growth factor(s) produced by SMCs themselves. We studied whether SMCs treated with IFN-y secreted growth factor(s) into the medium by using two different systems. First, medium-exchange experiments were conducted with growtharrested SMCs. Media were exchanged between SMCs treated with IFN-y for 24 hours and those treated with vehicle only ( Figure 4A ). [ Figure 4A ). Nontreated SMCs stayed growth arrested during the experiments. These data support the idea of secretion of growth factor(s) into the medium by SMCs treated with IFN-y. IFN-y-treated SMCs whose medium was replaced with that of nontreated SMCs, however, incorporated as much [ 3 H]TdR as did positive controls (data not shown), suggesting that additional mechanisms might be involved in the mitogenicity of IFN-y. Second, we evaluated the mitogenic activity in the conditioned medium of IFN-treated SMCs by using a 3T3 assay ( Figure 4B ). Swiss 3T3 cells originate from mice and do not respond to human IFN-y, which has stringent species specificity. 28 Conditioned media of IFN-ytreated SMCs were significantly more mitogenic than those of nontreated SMCs for 3T3 cells ( Figure 4B ). The result of the 3T3 assay indicated not only that IFN-y induced the secretion of mitogen(s) by SMCs but also that the mitogenic activity in the conditioned medium was not due to the minimal amount of IFN-y that had been carried over from previous IFN treatments.
To test whether the mitogenic activity observed was really due to IFN-y itself, the effect of an anti-IFN-y antibody was studied. The antibody eliminated all mitogenic activity induced by IFN-y for SMCs ( Figure 5 ). However, a control antibody or anti-PDGF antibody did not have any effects on the mitogenicity of IFN-y.
Autocrine Growth Factor(s) Induced by IFN-y Is Not PDGF
PDGF-AA has been reported to be produced by vascular SMCs as an autocrine growth factor. 26 - 2729 We conducted experiments to elucidate the potential role of PDGF-AA in IFN-y-induced mitogenicity. The anti-PDGF polyclonal antibody, which blocks the mitogenicity of exogenous PDGF-AA and -BB, failed to neutralize mitogenic activity in the conditioned medium of IFN-ytreated SMCs (Table 3) . Control IgG did not block the mitogenic activity in the conditioned medium. Furthermore, IFN-y did not reduce 125 I-PDGF-AA binding to SMCs in contrast to IL-1, which stimulated production of Conditioned medium (CM) of interferon gamma-treated smooth muscle cells was prepared as mentioned in the legend to Figure 4 . CM with or without platelet-derived growth factor (PDGF, 2 ngyiOO /il) was incubated with anti-PDGF immunoglobulin G (IgG) (2 jig/100 M>) or control goat IgG at 4°C for 30 minutes. One hundred microliters was added to Swiss 3T3 cells prepared as mentioned in "Methods." PDGF-AA 26 and downregulated 125 I-PDGF-AA binding ( Figure 6B ). These data indicate that the mitogenic activity induced by IFN-y is not PDGF-AA.
Upregulation of the PDGF-ft Receptor by IFN-y
Even when IFN-y was removed from the culture medium after a 24-hour treatment, the subsequent mitogenic response of the treated SMCs to PDGF was exaggerated (data not shown). This raised the possibility that IFN--y upregulated PDGF receptors. So we examined the effect of IFN-y on the PDGF receptors of SMCs. Human arterial SMCs, which we used for these experiments, express at least 10 times as many binding sites for PDGF-BB (34,000 sites/cell) than for PDGF-AA (2,000 sites/cell) ( Figures 6A and 7A) . The affinity of PDGF-AA and -BB to their binding sites were comparable with each other and had values as previously reported (/Cf=3.4xlO-M M and 2.5x10"" M, respectively). 22 Binding of 125 I-PDGF-AA to receptors competed with both PDGF-AA and -BB. On the other hand, binding of 1Z5 I-PDGF-BB barely competed with PDGF-AA (data not shown). These results suggested that the major type of PDGF receptor on the SMCs is the /3-receptor. 25 -30 IFN-y increased 125 I-PDGF-BB binding to SMCs in a dose-dependent fashion ( Figure  7B ). Scatchard plot analysis revealed that this was due to an increase in the number of binding sites ( Figure  7A) . A time-course experiment of 125 I-PDGF-BB binding revealed that upregulation of the preceptor became obvious 6 hours after addition of IFN-y and was maintained at the same level even after 48 hours ( Figure 7C ). Northern blot analysis (Figure 8 ) revealed that mRNA for the PDGF /3-receptor increased 2 hours after the addition of IFN-y, suggesting that the increase in /3-receptors is regulated at the level of mRNA.
Discussion
Indirect Mitogenic Activity of IFN-y on Vascular SMCs
In this paper we have shown that IFN-y by itself stimulates proliferation of SMCs and accentuates the mitogenicity of PDGF-BB for SMCs. This mitogenicity is partly due to the induction of autocrine growth factor(s), which was suggested by the presence of a time delay in the appearance of mitogenic effect of IFN-y. In fact, the conditioned medium of IFN-y-treated SMCs Figure 6 , and binding of I25 reported that IFN-y suppressed proliferation of cultured rat or human SMCs. We previously observed that IFN-y inhibited multiplication of cultured human umbilical arterial SMCs that were growing exponentially in the presence of 20% fetal calf serum. 15 To the best of our knowledge, this is the first report of mitogenic activity of IFN-y for SMCs. Factors that determine the direction of the effect of IFN-y on SMC proliferation are not yet clear. In our laboratory, the growing state of SMCs (i.e., quiescent or rapidly growing) seems to be a major factor. Other laboratories, however, have reported that IFN-y suppresses proliferation of SMCs released from G 0 /G r arrest by mitogens as well as exponentially growing SMCs. 14 ' 16 Another possible explanation might be the expression of different types of IFN-y receptor on SMCs under different culture conditions. So far, only one gene for a human IFN-y receptor has been cloned 35 ; however, the presence of multiple subtypes of IFN-y receptor has been reported in human monocytes/macrophages. subtypes of growth factor receptors has been proposed, based on a cross-linking study, to explain the bimodal effect of TGF-B on cell proliferation.
I-platelet-derived growth factor (PDGF)-BB to smooth muscle cells (SMCs). SMCs were prepared as mentioned in the legend to
1-PDGF-BB was determined as mentioned in "Methods." Panel A: Saturation binding curve of PDGF-BB to SMCs incubated for 24 hours in the presence (•-•) or absence (•-•) of interferon gamma (IFN-y, 10 units/ml). The inset shows the
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Autocrine Growth Factor(s) Induced by IFN-y Is Not PDGF-AA PDGF-AA is a well-known autocrine growth factor for vascular SMCs. Cultured SMCs prepared from atherosclerotic lesions secrete PDGF-like mitogenic activity into the culture medium. 29 IL-1 stimulates proliferation of SMCs and fibroblasts by inducing production of PDGF-AA by SMCs. 26 We investigated whether the autocrine growth factor(s) induced by IFN-y was PDGF-AA and found this not to be the case. One piece of evidence for this was the failure of antibody against PDGF to eliminate the mitogenic activity in culture medium conditioned with IFNtreated SMCs. Another was that IFN-y did not reduce 125 I-PDGF-AA binding to SMCs, whereas IL-1/3 reduced it transiently, as reported by Raines et al. 26 Mitogenic activity in the conditioned medium was not residual IFN-y either. The conditioned medium immediately induced DNA synthesis of SMCs unlike the time delay associated with IFN-y. The conditioned medium was mitogenic not only for SMCs but also for Swiss 3T3 cells, which originate from mice and therefore do not respond to human IFN-y. Taken together, this evidences suggests that IFN-y acts on SMCs and induces autocrine growth factor(s) that is different from PDGF or IFN-y.
SMCs potentially produce other mitogens, which include insulin-like growth factor (IGF)-I, 39 bFGF, 40 IL-1, 41 and some other unpurified growth factor(s). 42 Among them, IL-1 is not a likely candidate because of the evidence already mentioned above. Our preliminary experiments with an anti-insulin-like growth factor-I antibody also suggest that the factor is not IGF-I (data not shown). The exact identity of growth factor(s) induced by IFN-y remains a subject for further study.
Upregulation of PDGF ^-Receptor
We have demonstrated that IFN-y upregulates the expression of the PDGF /3-receptor but not the a-receptor. Bowen-Pope and Ross 43 reported a positive correlation between the number of PDGF receptors and the mitotic response of a cell to PDGF. They also reported that the presence of a certain subtype of PDGF receptor determines responsiveness to different dimers of PDGF, i.e., -AA, -AB, or -BB. 44 Upregulation of PDGF receptor expression partly explains the increase in sensitivity of SMCs to PDGF-BB after IFN-y treatment.
Although SMCs in normal arteries barely express the PDGF /3-receptor, they express the ^-receptor in atherosclerotic lesions 45 or in thickened intimas after balloon injury to the arterial wall. 46 In accordance with the expression of the receptor, PDGF-BB is produced in atherosclerotic lesions and promotes proliferation of SMCs.
2846 - 48 Until now it has been unclear as to what induces the PDGF ^-receptor on SMCs in the lesions. Our data indicate that IFN-y is a candidate for factors that upregulate PDGF /3-receptor expression in vascular lesions.
Hosang 28 reported that IFN-y inhibits proliferation of human skin fibroblasts in vitro without affecting the PDGF receptor. He used 125 I-PDGF-AB for his binding study. PDGF-AB binds mainly to the a subunit, 25 whose expression was not downregulated by IFN-y in our experiments.
Modulation of receptors for growth factors by IFN-y is not unique to SMCs. IFN-y suppresses proliferation of ECs by downregulating the endothelial cell growth factor receptor 32 and stimulates differentiation of melanoma cells by increasing the number of receptors for melanocyte-stimulating hormone. 49 
Pathophysiological Implications
Since IFN-y was found to suppress the proliferation of vascular SMCs in vitro, 9 data that suggest that IFN-y prevents the development of atherosclerotic lesions have been accumulated. There are SMCs expressing HLA-DR antigens in the atherosclerotic lesion. 13 IFN-y induces the expression of MHCII by SMCs in vitro, and MHC II-positive SMCs multiply less than do MHC II-negative SMCs in vivo. 9 Recombinant rat IFN-y suppresses the development of intimal thickening after balloon injury of rat carotid arteries. 50 Our data, however, suggest a possibility that IFN-y might accelerate lesion formation under certain circumstances. These situations might include atherosclerosis, 1 various types of vasculitis, and transplant arteriosclerosis, 51 in which the infiltration of numerous lymphocytes is observed. The roles of the mitogenic activity of IFN-y in vivo as well as the factor that determines the direction of the action of IFN-y on cell proliferation remains an area for further study.
